Epstein–Barr virus-positive mucocutaneous ulcer in Crohn's disease. A condition to consider in immunosuppressed IBD patients

Alba Juan*, Triana Lobatón, Gustavo Tapia, Míriam Mañosa, Eduard Cabré, Eugeni Domènech

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

23 Citations (Scopus)

Abstract

Epstein–Barr virus-positive mucocutaneous ulcer (EBVMCU) is a little known entity that can affect the oropharyngeal mucosa, the gastrointestinal tract and the skin. The main risk factor for the development of this lesion is immunosuppression. Because its features are similar to other Epstein–Barr virus-associated lymphoproliferative disorders, a differential diagnosis can sometimes prove challenging. Here, we report the case of a man diagnosed with Crohn's disease and treated with azathioprine and infliximab who developed ulceration at the rectum that was refractory to conventional medical treatment. Although the histological characteristics were suggestive of an EBVMCU, lymphoproliferative disease could not be ruled out. The patient did not improve after discontinuation of the treatment, a proctectomy was performed and the diagnosis of this disease was confirmed. Although very few cases of EBVMCU affecting the colon have been reported, its diagnosis should be always considered in refractory cases of inflammatory bowel disease with patients undergoing immunosuppressive treatment.

Original languageAmerican English
Pages (from-to)934-937
Number of pages4
JournalDigestive and Liver Disease
Volume49
Issue number8
DOIs
Publication statusPublished - Aug 2017

Keywords

  • Crohn's disease
  • EBV mucocutaneous ulcer
  • Infliximab

Fingerprint

Dive into the research topics of 'Epstein–Barr virus-positive mucocutaneous ulcer in Crohn's disease. A condition to consider in immunosuppressed IBD patients'. Together they form a unique fingerprint.

Cite this